SAB Biotherapeutics' Series A Round

SAB Biotherapeutics raised a round of funding on August 28, 2018. Investors include T. Denny Sanford.

SAB Biotherapeutics (SAB), headquartered in Sioux Falls, S.D. is a clinical stage, biopharmaceutical development company focused on the manufacturing of antibody therapeutics. SAB delivers a platform …

Articles about SAB Biotherapeutics' Series A Round: